CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 58 enrolled
Drug / intervention
Daclatasvirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01830205
NCT01830205Phase 1Completed
CompareCT.gov

Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment

Bristol-Myers Squibb·interventional·Posted Apr 12, 2013·Updated Nov 16, 2015

In Brief

A Phase 1 clinical trial evaluating Daclatasvir for Hepatitis C. Completed, enrolled 58 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 12, 2013
Enrollment StartSep 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.2 years ago

Interventions

Daclatasvirdrug